Expertise
The sectors we work in.
The functions we've run.
SVI's coverage is grounded in more than two decades of operating and executive experience, not secondary-source familiarity. Four areas lead the practice. The additional areas and functions below are ones where that experience is also direct.
Primary focus
Oncology
Development, portfolio, commercial, partnering, and investment assessment across oncology assets, including direct experience leading cross-functional development teams and companion-diagnostic strategy.
Radiopharma & Theranostics
Development, isotope and supply considerations, nuclear medicine operations, manufacturing and distribution constraints, regulatory and reimbursement issues, site-of-care economics, commercialization, and investment assessment.
Diagnostics, IVD & NGS
Diagnostic and molecular-testing strategy, coding and reimbursement, health economics, laboratory and channel models, ordering behavior, IP issue spotting, partnering, operating design, and investment evaluation.
Medical Devices / MedTech
Strategy and diligence across hospital and interventional devices, including clinical requirements, regulatory implications, hospital purchasing and GPO dynamics, reimbursement, adoption, partnering, valuation, and transaction strategy.
Additional direct experience
CNS & Pain
Strategy, development, diligence, licensing, and portfolio assessment across CNS and pain-management assets, including drug-delivery technologies, differentiated formulations, abuse-deterrent approaches, and selected neurologic therapies.
Rare & Orphan Disease
Portfolio strategy and diligence across rare-disease opportunities, including patient identification, clinical and regulatory considerations, market access, orphan-drug economics, specialized distribution, and valuation.
Biopharma, Biologics & Biosimilars
Asset and portfolio assessment across pharmaceuticals, biologics, and biosimilars, including global asset search, manufacturing, regulatory pathway, lifecycle, licensing, commercialization, and valuation considerations.
Cross-functional capabilities
Diligence questions do not stay inside one function. The analysis follows the question across the functions below, not the boundary of a single practice area.
- Strategy & Portfolio Management
- Corporate Development, M&A & BD&L
- R&D / Clinical Development Strategy
- Market Access, Reimbursement & HEOR
- Commercialization & Global Go-to-Market
- Manufacturing, Supply & Operating Model
- Valuation, eNPV & Capital Prioritization
SVI uses AI-enabled analysis selectively where it can improve speed, pattern recognition, or scenario development, with senior review and source verification. When AI itself is material to the investment thesis, SVI can also evaluate it as a potential operating or value-creation lever.